...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in lipidology >Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
【24h】

Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?

机译：糖尿病前期/代谢综合征患者的血脂降低：有什么证据？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Both the metabolic syndrome and prediabetes are associated with increased coronary risk. Lipoprotein abnormalities are among the many factors that may contribute to this. The present review focuses on these abnormalities and the evidence indicating that correcting them may reduce the risk. RECENT FINDINGS: Many drugs, both old and in development, may be able to correct lipoprotein abnormalities. No clinical trials are specifically designed to examine the effects of lipid intervention on coronary risk in the metabolic syndrome. Data from subgroup analyses and extrapolation from studies in those with and without diabetes have led to recommendations about the benefits and the targets for lipoprotein treatment. SUMMARY: The primary goal of lipoprotein treatment is to bring the LDL-C to target levels. Thereafter, if plasma triglycerides are high and HDL-C is low, these should be corrected.
机译：审查目的：代谢综合征和糖尿病前期患者都与冠心病风险增加相关。脂蛋白异常可能是造成这种情况的众多因素之一。本综述着重于这些异常现象以及表明纠正这些异常现象可以降低风险的证据。最近的发现：许多旧的和开发中的药物都可能能够纠正脂蛋白异常。没有专门设计的临床试验来检查脂质干预对代谢综合征冠心病风险的影响。来自亚组分析的数据和来自有或没有糖尿病患者的研究推断得出的结果，都提出了有关脂蛋白治疗的益处和目标的建议。简介：脂蛋白治疗的主要目标是使LDL-C达到目标水平。此后，如果血浆甘油三酸酯高而HDL-C低，则应予以纠正。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号